Omadacycline Tissue Penetration in Diabetic Patients With Wound Infections and Healthy Volunteers Via In Vivo Microdialysis
Status:
Completed
Trial end date:
2021-07-29
Target enrollment:
Participant gender:
Summary
This study will determine the tissue penetration of the novel tetracycline antibiotic,
omadacycline (Nuzyra, Paratek Pharmaceuticals, Inc.), into the extracellular, interstitial
fluid of soft tissue in diabetic patients with lower limb wound infections. Penetration will
be compared with a group of healthy volunteer control participants.